Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
Go back to Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)| Merck & Co. (NYSE: MRK) | Delayed: 119.05 -1.71 (1.42%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $120.76 | 52 Week High | $65.46 | |||
| Open | $121.50 | 52 Week Low | $47.97 | |||
| Day High | $121.90 | P/E | 80.99 | |||
| Day Low | $118.83 | EPS | $1.47 | |||
| Volume | 10,927,028 | |||||
| (NASDAQ: TERN) | Delayed: 52.95 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $52.95 | 52 Week High | $ | |||
| Open | $52.95 | 52 Week Low | $ | |||
| Day High | $52.95 | P/E | N/A | |||
| Day Low | $52.95 | EPS | $ | |||
| Volume | 58,940 | |||||
